Articles by Alan Tan, MD
The panel shared their excitement for the road ahead in kidney cancer.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Dr. Alan Tan compares the PSMAfore and VISION studies and comments on the controversy regarding OS benefit in the former.
The FDA may allow the temporary use of drugs from overseas to alleviate the ongoing cisplatin and carboplatin shortages.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.